Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 138-142

  Prince, F H M ^a   Geerdink, L M ^a   Borsboom, G J J M ^b   Twilt, M ^a   Van Rossum, M A J ^c,d   Hoppenreijs, E P A H ^e   Ten Cate, R ^f   Koopman Keemink, Y ^g   Van Santen Hoeufft, M ^h   Raat, H ^b   Van Suijlekom Smit, L W A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d JAN VAN BREEMEN INSTITUTE   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JULIANA CHILDREN S HOSPITAL   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FAMILY; FEMALE; HEALTH UTILITY INDEX MARK 3; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WELLBEING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 73449146297     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.111260     Document Type: Article

References (40)

1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002;29:1520-30.
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
3. Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
4. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41:1428-35.
5. Bloom BJ. New drug therapies for the pediatric rheumatic diseases. Curr Opin Rheumatol 2001;13:410-4.
6. Gartlehner G, Hansen RA, Jonas BL, et al. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 2008;27:67-76.
7. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
8. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
9. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
10. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2006;20:279-300.
11. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
12. Hampton T. Trials reveal promising options for treating juvenile rheumatoid arthritis. JAMA 2008;299:27-8.
13. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84.
14. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
15. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
16. Tynjala P, Vahasalo P, Honkanen V, et al. Drug survival of the first and second course of anti-TNF agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:552-7.
17. Robinson RF, Nahata MC, Hayes JR, et al. Quality-of-life measurements in juvenile rheumatoid arthritis patients treated with etanercept. Clin Drug Investig 2003;23:511-18.
18. Wulffraat N, van der Net JJ, Ruperto N, et al. The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S111-5.
19. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Rheum Dis Clin North Am 2007;33:389-402.
20. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess 2001;5:1-157.
21. Prince FH, Ferket IS, Kamphuis S, et al. Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl. Rheumatology (Oxford) 2008;47:1413-6.
22. Raat H, Bonsel GJ, Essink-Bot ML, et al. Reliability and validity of comprehensive health status measures in children: the Child Health Questionnaire in relation to the Health Utilities Index. J Clin Epidemiol 2002;55:67-76.
23. Raat H, Bonsel GJ, Hoogeveen WC, et al. Feasibility and reliability of a mailed questionnaire to obtain visual analogue scale valuations for health states defined by the Health Utilities Index Mark 3. Med Care 2004;42:13-8.
24. Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001;19:S1-9.
25. Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
26. Landgraf JM, Abetz L, Ware JE Jr. The CHQ user's manual. 1st ed. Boston: The Health Institute, New England Medical Center, 1996.
27. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002;40:113-28.
28. Prince FH, Twilt M, Jansen-Wijngaarden NC, et al. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007;66:704-5.
29. Prince FH, van Suijlekom-Smit LW. Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis. Rheumatol Int 2008;28:397-8, author reply 399.
30. Riddle R, Ryser CN, Morton AA, et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol 2006;31:262-71.
31. Shaw KL, Southwood TR, Duffy CM, et al. Health-related quality of life in adolescents with juvenile idiopathic arthritis. Arthritis Rheum 2006;55:199-207.
32. Arkela-Kautiainen M, Haapasaari J, Kautiainen H, et al. Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF model. J Rheumatol 2006;33:1369-76.
33. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763- 9.
34. Reiff A. Childhood quality of life in the changing landscape of pediatric rheumatology. J Pediatr (Rio J) 2008;84:285-8.
35. Amine B, Rostom S, Benbouazza K, et al. Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis. Rheumatol Int 2009;29:275-9.
36. Gutierrez-Suarez R, Pistorio A, Cespedes Cruz A, et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology (Oxford) 2007;46:314-20.
37. Oliveira S, Ravelli A, Pistorio A, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum 2007;57:35-43.
38. Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:309-14.
39. Huygen AC, Kuis W, Sinnema G. Psychological, behavioural, and social adjustment in children and adolescents with juvenile chronic arthritis. Ann Rheum Dis 2000;59:276-82.
40. Moorthy LN, Peterson MG, Harrison MJ, et al. Physical function assessment tools in pediatric rheumatology. Pediatr Rheumatol Online J 2008;6:9.